Comprehensive Evaluation of the NeoBase 2 Non-derivatized MSMS Assay and Exploration of Analytes With Significantly Different Concentrations Between Term and Preterm Neonates.

Beomki Lee Won Young Heo Jee Ah Kim Hyun-Seung Lee Narae Hwang Hyung-Doo Park Se In Sung Yun Sil Chang Won Soon Park Soo-Youn Lee

Published in: Annals of laboratory medicine (2022)

The NeoBase 2 assay demonstrated satisfactory performance. The additional analytes provide a wider diagnostic coverage, and the simultaneous measurement of Tyr and SUAC is efficient in excluding TYR 1. The new cutoffs for preterm neonates may decrease false-positive rates, without compromising diagnostic sensitivity.

Keyphrases

low birth weight
preterm infants
gestational age
preterm birth
high throughput
affordable care act